Longitudinal Changes in Recovery from Drug Use Disorders: A National Study

吸毒障碍康复的纵向变化:一项全国研究

基本信息

项目摘要

 DESCRIPTION (provided by applicant): This project "Longitudinal Changes in Recovery from Drug Use Disorders: A National Study" proposes to use two waves of nationally representative longitudinal data to examine the course of drug use disorders (DUDs) along with longitudinal changes in recovery from DUDs, including rates and correlates of relapse (i.e., recurrence of any DUD criteria) and full remission (i.e., no recurrence of any DUD criteria). To date, there is limited knowledge on the stability of full remission from DUDs based on nationally representative studies in the U.S. because the majority of research has focused solely on alcohol use disorders (AUDs) and treatment samples. There has been a significant shift in primary drugs of abuse observed in those entering drug abuse treatment programs in the U.S. over the past two decades with the percentage of drug abuse treatment admissions reporting alcohol as the primary drug of abuse decreasing from 57% in 1993 to 41% in 2010, while the percentage of drug abuse treatment admissions for marijuana, opiates, and stimulants increased from approximately 22% in 1993 to 47% in 2010. While the course of AUDs and recovery from AUDs has been well-investigated in the general population, no nationally representative studies have examined the longitudinal patterns of DUDs and recovery from DUDs over time and potential differences between DUDs involving individual drug classes (e.g., sedative, tranquilizer, opioid, stimulant, hallucinogen, cannabis, cocaine, heroin, and inhalant) o DUDs involving multiple drug classes. In order to address these gaps, we propose a secondary analysis of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), a two-wave longitudinal and epidemiological survey of a nationally representative sample of 34,653 non-institutionalized adults, 18 years of age or older residing in the U.S. The NESARC represents the only large-scale nationally representative study that has a sufficient sample size to assess potential differences in drug classes, age, gender, and race/ethnicity, to meet our study purpose which aims to: (1) assess the prevalence of recovery from DUDs (i.e., drug-specific DUDs and DUDs involving multiple drug classes) at Wave 1 (baseline) and Wave 2 (3 years later); (2) determine whether DUD recovery status at Wave 1 (baseline) is associated with the likelihood of reinterview at Wave 2 (3 years later), and examine the sensitivity of inferences regarding DUD recovery status at Wave 2 to potential differential attrition; (3) examine the predictors from multiple developmental domains associated with relapse and full remission; and (4) investigate the effects of drug abuse treatment utilization and disability on recovery from DUDs at Waves 1 and 2. The proposed project takes advantage of the unique opportunities afforded by the NESARC. These include: the availability of a large nationally representative sample of non-institutionalized adults; large numbers of individuals with DUD; the inclusion of developmentally relevant predictors associated with relapse; and the inclusion of reliable measures of disability, treatment utilization, DUDs and other psychiatric disorders.
 描述(由申请人提供):本项目“药物使用障碍恢复的纵向变化:一项全国性研究”建议使用两波具有全国代表性的纵向数据来检查药物使用障碍(DUD)的病程沿着药物使用障碍恢复的纵向变化,包括复发率和相关因素(即,任何DUD标准的复发)和完全缓解(即,没有重复出现任何DUD标准)。迄今为止,基于美国的全国代表性研究,对DUD完全缓解的稳定性的了解有限,因为大多数研究仅关注酒精使用障碍(AUD)和治疗样本。在过去的二十年里,在美国进入药物滥用治疗项目的人中观察到的主要药物滥用发生了重大变化,报告酒精作为主要药物滥用的药物滥用治疗入院率从1993年的57%下降到2010年的41%,而大麻,阿片类药物,兴奋剂从1993年的约22%上升到2010年的47%。虽然在一般人群中对AUDs的病程和AUDs的恢复进行了充分的研究,但没有全国性的代表性研究考察了DUDs的纵向模式和DUDs随时间的恢复以及涉及单个药物类别的DUDs之间的潜在差异(例如,镇静剂、安定剂、阿片类药物、兴奋剂、致幻剂、大麻、可卡因、海洛因和吸入剂)。为了解决这些差距,我们建议对全国酒精及相关疾病流行病学调查(NESARC)进行二次分析,这是一项对34,653名非机构化成年人的全国代表性样本进行的两波纵向和流行病学调查,18岁或以上居住在美国的NESARC代表了唯一的大型-一项具有足够样本量的全国代表性研究,以评估药物类别、年龄、性别和种族/民族的潜在差异,以满足我们的研究目的,其目的是:(1)评估DUD恢复的流行率(即,药物特异性DUD和涉及多种药物类别的DUD)(基线)和第2波(3年后);(2)确定第1波时DUD恢复状态(基线)与第2波重新面谈的可能性相关(3年后),并检查关于第2波DUD恢复状态的推断对潜在差异磨损的敏感性;(3)检查与复发和完全缓解相关的多个发育领域的预测因素;(4)研究药物滥用治疗利用和残疾对第1波和第2波DUD恢复的影响。拟议的项目利用了NESARC提供的独特机会。其中包括:非机构化成人的大量全国代表性样本的可用性;大量DUD个体;纳入与复发相关的发育相关预测因子;以及纳入残疾,治疗利用,DUD和其他精神疾病的可靠措施。

项目成果

期刊论文数量(28)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sources of opioid medication for misuse in older adults: results from a nationally representative survey.
  • DOI:
    10.1097/j.pain.0000000000001241
  • 发表时间:
    2018-08
  • 期刊:
  • 影响因子:
    7.4
  • 作者:
    Schepis TS;McCabe SE;Teter CJ
  • 通讯作者:
    Teter CJ
Prescription opioid and benzodiazepine misuse is associated with suicidal ideation in older adults.
Associations Among Childhood Household Dysfunction, Sexual Orientation, and DSM-5 Alcohol, Tobacco and Other Substance Use Disorders in Adulthood: Evidence From a National U.S. Survey.
  • DOI:
    10.1097/adm.0000000000000641
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    McCabe SE;Hughes TL;West BT;Evans-Polce R;Veliz P;Dickinson K;Hoak S;Boyd CJ
  • 通讯作者:
    Boyd CJ
Association of transphobic discrimination and alcohol misuse among transgender adults: Results from the U.S. Transgender Survey.
  • DOI:
    10.1016/j.drugalcdep.2020.108223
  • 发表时间:
    2020-10-01
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Kcomt L;Evans-Polce RJ;Boyd CJ;McCabe SE
  • 通讯作者:
    McCabe SE
Prescription Opioid Misuse in US Older Adults: Associated Comorbidities and Reduced Quality of Life in the National Epidemiologic Survey of Alcohol and Related Conditions-III.
美国老年人处方阿片类药物滥用:全国酒精及相关疾病流行病学调查中的相关合并症和生活质量下降 - III。
  • DOI:
    10.4088/jcp.19m12853
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Schepis,TyS;McCabe,SeanEsteban
  • 通讯作者:
    McCabe,SeanEsteban
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SEAN ESTEBAN MCCABE其他文献

SEAN ESTEBAN MCCABE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SEAN ESTEBAN MCCABE', 18)}}的其他基金

Health, Stress, and Tobacco Use Disparities among Sexual Minority Populations
性少数人群的健康、压力和烟草使用差异
  • 批准号:
    9380175
  • 财政年份:
    2017
  • 资助金额:
    $ 21.62万
  • 项目类别:
E-Cigarette Use and Longitudinal Changes in Cigarette Smoking and Health
电子烟的使用以及吸烟与健康的纵向变化
  • 批准号:
    9339655
  • 财政年份:
    2016
  • 资助金额:
    $ 21.62万
  • 项目类别:
E-Cigarette Use and Longitudinal Changes in Cigarette Smoking and Health
电子烟的使用以及吸烟与健康的纵向变化
  • 批准号:
    9077678
  • 财政年份:
    2016
  • 资助金额:
    $ 21.62万
  • 项目类别:
Trajectories of Nonmedical Prescription Drug Misuse
非医疗处方药滥用的轨迹
  • 批准号:
    9096030
  • 财政年份:
    2015
  • 资助金额:
    $ 21.62万
  • 项目类别:
Trajectories of Nonmedical Prescription Drug Misuse
非医疗处方药滥用的轨迹
  • 批准号:
    8233989
  • 财政年份:
    2011
  • 资助金额:
    $ 21.62万
  • 项目类别:
Trajectories of Nonmedical Prescription Drug Misuse
非医疗处方药滥用的轨迹
  • 批准号:
    8445325
  • 财政年份:
    2011
  • 资助金额:
    $ 21.62万
  • 项目类别:
Trajectories of Nonmedical Prescription Drug Misuse
非医疗处方药滥用的轨迹
  • 批准号:
    9908065
  • 财政年份:
    2011
  • 资助金额:
    $ 21.62万
  • 项目类别:
Trajectories of Nonmedical Prescription Drug Misuse
非医疗处方药滥用的轨迹
  • 批准号:
    8083034
  • 财政年份:
    2011
  • 资助金额:
    $ 21.62万
  • 项目类别:
Sexual Orientation, Substance Use and Mental Health
性取向、药物滥用和心理健康
  • 批准号:
    7384322
  • 财政年份:
    2007
  • 资助金额:
    $ 21.62万
  • 项目类别:
Sexual Orientation, Substance Use and Mental Health
性取向、药物滥用和心理健康
  • 批准号:
    7501921
  • 财政年份:
    2007
  • 资助金额:
    $ 21.62万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.62万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了